Akeso, Inc. has officially announced that the National Medical Products Administration (NMPA) in China has accepted its supplementary New Drug Application (sNDA) for ivonescimab, a PD-1/VEGF bispecific antibody. The application seeks approval for ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). […]
Featured News
CD40/CD40L Inhibitors: Unlocking the Future of Autoimmune and Transplant Therapies
DelveInsight’s comprehensive analysis of the CD40/CD40L inhibitors market delivers a detailed understanding of current treatment trends, the scope of the target population, and an evaluation of the competitive landscape with a forecast extending to 2034. The report places emphasis on indications where CD40/CD40L inhibitors hold potential, including systemic lupus erythematosus […]
Matrix Deepens Commitment to In-Home Care with New Diagnostic Partner
Matrix Medical Network, a recognized leader in delivering high-quality, home-based healthcare services, has announced a strategic partnership with Molecular Testing Labs (MTL), a CLIA- and New York State-certified, CAP-accredited laboratory known for its innovation and excellence in molecular diagnostics. This collaboration marks a significant step forward in Matrix’s ongoing commitment […]
Revolutionizing Melanoma Care: SkylineDx’s CP-GEP Test Minimizes Surgical Risks
SkylineDx, a leading diagnostics innovator specializing in molecular diagnostics for oncology, inflammatory, and infectious diseases, has announced significant findings from a Danish validation study recently published in the Journal of Surgical Oncology. This study confirms that SkylineDx’s Merlin Assay, also known as CP-GEP, can accurately identify cutaneous melanoma patients, particularly […]
Texas Cardiac Arrhythmia Institute First in U.S. to Implant Leadless Heart Failure Therapy Device
The Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center electrophysiologists have achieved a significant milestone by being the first medical team in the US to implant a novel, FDA-approved leadless device intended to provide cardiac resynchronization therapy to patients with heart failure. This therapy plays a vital role […]
Saluda Medical Rolls Out EVA Nationwide: A Breakthrough in Spinal Cord Stimulation Treatment
Saluda Medical, Inc., a leader in the advancement of neuromodulation technologies aimed at improving the lives of patients with chronic neurological disorders, has formally declared EVA’s full-scale commercial availability, its most recent advancements in sensing technology, all around the United States. This comes after EVA was approved by the US […]
FDA Grants Orphan Drug Designation to Amphix Bio’s Spinal Cord Injury Treatment
Amphix Bio, an innovative pre-clinical stage biotechnology company, has announced that its lead therapeutic candidate, AMFX-200, has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of acute spinal cord injury (SCI). This condition, which affects approximately 18,000 individuals annually in the United States, often […]
Microcurrent Therapy From Berlin Heals Shows Disease-Modifying Potential in Heart Failure Patients
Berlin Heals, an innovator in the field of bioelectric medicine aimed at treating heart failure, has announced the publication of a groundbreaking peer-reviewed study in the ESC Heart Failure journal. The study, titled “Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot study,” highlights the […]
FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance
FinThrive, Inc., a leading healthcare revenue management software-as-a-service (SaaS) provider, will have a significant presence at the 2025 Healthcare Financial Management Association (HFMA) Annual Conference, which will take place June 22-25 in Denver, Colorado. With high-profile speaking engagements, live demonstrations of cutting-edge solutions, and Agentic AI-driven innovation, FinThrive will showcase how its revenue cycle […]
NeuralCure AI Launches the First Diagnostic & Digital Twin OS for Preventative Care Clinics
NeuralCure AI today announced the official launch of its groundbreaking Diagnostic & Digital Twin Operating System, the first infrastructure platform purpose-built for the exploding preventative, regenerative, and patient-led healthcare market. As millions of Americans take control of their health, ordering their own labs and imaging, using AI to self-navigate symptoms, […]
